DM Clinical Research, a national network of clinical trial sites, has opened its first research location in the Boston metropolitan area and Massachusetts. The Houston, Texas-headquartered company also announced it will soon start enrolling patients in Moderna’s CMVictory Trial studying mRNA-1647, an investigational vaccine, to understand whether it can help the immune system protect against cytomegalovirus (CMV).
Moderna was among the key biopharma and community partners that joined DM Clinical Research for a ribbon cutting celebration and tours of the 4,000-square-foot research site, which includes patient rooms, laboratory facilities, and vaccine storage and preparation rooms. The site address is 77 Pond Avenue, Suite 205C in Brookline.
The Boston site enhances our ability to offer research sponsors access to a diverse patient footprint that already includes underserved communities in Chicago, Detroit, Houston and Philadelphia.”
“DM Clinical Research is in a period of rapid growth with multiple new study sites added over the last two years in addition to the quadrupling of our staff to over 500 employees,” said DM Clinical Research Founder & CEO Mohammad Millwala. “We expect this transformational growth trajectory to continue for the foreseeable future, on the road to becoming the leading independent clinical research network in the nation.”
Comments powered by CComment